These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 35669974)

  • 1. Surrogate Endpoints for Late Kidney Transplantation Failure.
    Naesens M; Budde K; Hilbrands L; Oberbauer R; Bellini MI; Glotz D; Grinyó J; Heemann U; Jochmans I; Pengel L; Reinders M; Schneeberger S; Loupy A
    Transpl Int; 2022; 35():10136. PubMed ID: 35669974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale for Surrogate Endpoints and Conditional Marketing Authorization of New Therapies for Kidney Transplantation.
    Naesens M; Loupy A; Hilbrands L; Oberbauer R; Bellini MI; Glotz D; Grinyó J; Heemann U; Jochmans I; Pengel L; Reinders M; Schneeberger S; Budde K
    Transpl Int; 2022; 35():10137. PubMed ID: 35669977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Redefining Risk Stratification and Endpoints for Clinical Trials in Kidney Transplantation: Rationale and Methodology of Proposals Submitted to the European Medicines Agency by the European Society for Organ Transplantation.
    Naesens M; Schneeberger S;
    Transpl Int; 2022; 35():10142. PubMed ID: 35992750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proposed Definitions of Antibody-Mediated Rejection for Use as a Clinical Trial Endpoint in Kidney Transplantation.
    Roufosse C; Becker JU; Rabant M; Seron D; Bellini MI; Böhmig GA; Budde K; Diekmann F; Glotz D; Hilbrands L; Loupy A; Oberbauer R; Pengel L; Schneeberger S; Naesens M
    Transpl Int; 2022; 35():10140. PubMed ID: 35669973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of graft failure after first detection of de novo donor-specific HLA antibodies in kidney transplant recipients.
    López Del Moral C; Wu K; Naik M; Osmanodja B; Akifova A; Lachmann N; Stauch D; Hergovits S; Choi M; Bachmann F; Halleck F; Schrezenmeier E; Schmidt D; Budde K
    Nephrol Dial Transplant; 2023 Dec; 39(1):84-94. PubMed ID: 37410616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allograft Function as Endpoint for Clinical Trials in Kidney Transplantation.
    Hilbrands L; Budde K; Bellini MI; Diekmann F; Furian L; Grinyó J; Heemann U; Hesselink DA; Loupy A; Oberbauer R; Pengel L; Reinders M; Schneeberger S; Naesens M
    Transpl Int; 2022; 35():10139. PubMed ID: 35669976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of the Definition of Rejection in Kidney Transplantation and Its Use as an Endpoint in Clinical Trials.
    Becker JU; Seron D; Rabant M; Roufosse C; Naesens M
    Transpl Int; 2022; 35():10141. PubMed ID: 35669978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alloimmune Risk Stratification for Kidney Transplant Rejection.
    Bestard O; Thaunat O; Bellini MI; Böhmig GA; Budde K; Claas F; Couzi L; Furian L; Heemann U; Mamode N; Oberbauer R; Pengel L; Schneeberger S; Naesens M
    Transpl Int; 2022; 35():10138. PubMed ID: 35669972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing the prognostic performance of iBOX and biopsy-proven acute rejection for long-term kidney graft survival.
    Klein A; Kosinski L; Loupy A; Frey E; Stegall M; Helanterä I; Newell K; Meier-Kriesche HU; Mannon RB; Fitzsimmons WE;
    Am J Transplant; 2024 Oct; 24(10):1784-1793. PubMed ID: 38642711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design.
    Nickerson PW; Böhmig GA; Chadban S; Kumar D; Mannon RB; van Gelder T; Lee JC; Adler S; Chong E; Djamali A
    Trials; 2022 Dec; 23(1):1042. PubMed ID: 36550562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab.
    Kahwaji J; Jordan SC; Najjar R; Wongsaroj P; Choi J; Peng A; Villicana R; Vo A
    Transpl Int; 2016 Dec; 29(12):1276-1285. PubMed ID: 27529314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proposed Definitions of T Cell-Mediated Rejection and Tubulointerstitial Inflammation as Clinical Trial Endpoints in Kidney Transplantation.
    Seron D; Rabant M; Becker JU; Roufosse C; Bellini MI; Böhmig GA; Budde K; Diekmann F; Glotz D; Hilbrands L; Loupy A; Oberbauer R; Pengel L; Schneeberger S; Naesens M
    Transpl Int; 2022; 35():10135. PubMed ID: 35669975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kidney Transplantation From Old Deceased Donors: Impact of Uric Acid Level-A Quarter-Century of Experience in One Transplant Center.
    Magott-Procelewska M; Madziarska K; Boratynska M; Chudoba P; Lepiesza A; Mazanowska O; Zmonarski S; Madziarski M; Hap K; Klinger M
    Transplant Proc; 2018; 50(6):1701-1704. PubMed ID: 30056885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
    Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
    Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial.
    Eskandary F; Bond G; Schwaiger E; Kikic Z; Winzer C; Wahrmann M; Marinova L; Haslacher H; Regele H; Oberbauer R; Böhmig GA
    Trials; 2014 Apr; 15():107. PubMed ID: 24708575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling graft loss in patients with donor-specific antibody at baseline using the Birmingham-Mayo (BirMay) predictor: Implications for clinical trials.
    Bentall A; Smith BH; Gonzales MM; Bonner K; Park WD; Cornell LD; Dean PG; Schinstock CA; Borrows R; Lefaucheur C; Loupy A; Stegall MD
    Am J Transplant; 2019 Aug; 19(8):2274-2283. PubMed ID: 30768833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of HLA antibodies on graft survival in long-term renal recipients with functional grafts.
    Zeng Y; Liu Z; Liu Y; Fan Y; Guo Y; Qiu J
    Urol Int; 2014; 92(3):328-33. PubMed ID: 24480999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can a combined screening/treatment programme prevent premature failure of renal transplants due to chronic rejection in patients with HLA antibodies: study protocol for the multicentre randomised controlled OuTSMART trial.
    Dorling A; Rebollo-Mesa I; Hilton R; Peacock JL; Vaughan R; Gardner L; Danzi G; Baker R; Clark B; Thuraisingham RC; Buckland M; Picton M; Martin S; Borrows R; Briggs D; Horne R; McCrone P; Kelly J; Murphy C
    Trials; 2014 Jan; 15():30. PubMed ID: 24447519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term kidney transplant outcomes among African American recipients do not predict long-term outcomes: donor pair analysis.
    Keith D; Patrie JT
    Clin Transplant; 2011; 25(1):69-76. PubMed ID: 20201952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of angiotensin II type 1 receptor antibodies with graft histology, function and survival in paediatric renal transplant recipients.
    Fichtner A; Süsal C; Schröder C; Höcker B; Rieger S; Waldherr R; Westhoff JH; Sander A; Dragun D; Tönshoff B
    Nephrol Dial Transplant; 2018 Jun; 33(6):1065-1072. PubMed ID: 29444269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.